Stock Insider Trading (from SEC Form 4)

ATRC / AtriCure, Inc. insiders include Lanning Mark R, WEHRWEIN SVEN, Drake Scott William, and GROVES REGINA E, Kennedy Patricia J (VP and GM, International), LUX ANDREW L (SVP, Ops & Quality), JOHNSON B KRISTINE, Noznesky Justin J (SVP, Mktg & Business Develop), Privitera Salvatore (Chief Technology Officer), ROBARDS KAREN P, Collar Mark A, Hooven Michael D Wade M. Andrew (SVP and CFO), Krell Elizabeth D, WHITE ROBERT S., JOHNSTON RICHARD M, Seith Douglas J (Chief Operating Officer), CARREL MICHAEL H (President, CEO, & Director), .

AtriCure, Inc. insider trades are found here. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

Job titles are listed as of the filing and may not be current. Click the link icon to see the full transaction history.

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.
File Date
Tran Date
Insider Code Shares Post Shares Percent
Tran Value Post Value Percent
2018-02-16 2018-02-15 Noznesky Justin J SVP, Mktg & Business Develop
S -4,000 124,997 -3.10 17.03 -68,120 2,128,699 -3.20
2018-01-26 2018-01-24 Wade M. Andrew SVP and CFO
F -3,791 158,730 -2.33 17.55 -66,532
2018-01-26 2018-01-24 Seith Douglas J Chief Operating Officer
F -3,275 240,920 -1.34 17.55 -57,476
2018-01-26 2018-01-24 CARREL MICHAEL H President, CEO, & Director, Director
F -33,167 636,676 -4.95 17.55 -582,081
2018-01-22 2018-01-18 Collar Mark A Director
M 25,000 69,067 56.73 13.31 332,750
2017-11-09 2017-11-08 JOHNSON B KRISTINE Director
P 1,500 10,969 15.84 18.36 27,540 201,391 13.67
2017-08-23 2017-08-22 Krell Elizabeth D Director
S -10,000 19,967 -33.37 22.40 -224,000 447,261 -50.08
2017-07-25 2017-07-24 Privitera Salvatore Chief Technology Officer
A 60,000 66,000 1,000.00
2017-07-05 2017-06-30 LUX ANDREW L SVP, Ops & Quality
A 960 66,549 1.46 16.32 15,667
2017-06-08 2017-06-07 Lanning Mark R Director
M 10,000 90,805 12.38 9.50 95,000
2017-05-25 2017-05-24 Drake Scott William Director
A 5,805 5,805
2017-05-25 2017-05-24 JOHNSTON RICHARD M Director
A 5,805 5,805
2017-05-25 2017-05-24 WEHRWEIN SVEN Director
A 5,805 5,805
2017-05-25 2017-05-24 WHITE ROBERT S. Director
A 5,805 8,605 207.32
2017-05-09 2017-05-05 Hooven Michael D Director
M 10,000 553,892 1.84 9.50 95,000
2017-03-23 2017-03-21 GROVES REGINA E Director
A 9,469 9,469
2016-12-20 2016-12-19 ROBARDS KAREN P Director
G -5,000 318,328 -1.55
2015-10-29 2015-10-27 Kennedy Patricia J VP and GM, International
F -455 63,124 -0.72 19.39 -8,822
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)

Related News Stories

Biotech Daily Digest For January 16th

2018-01-16 seekingalpha
Biotech is rising in 2018 but still lags other sectors that will see more direct impacts from the recently passed tax legislation. (685-1)

AtriCure's (ATRC) CEO Michael Carrel on Q3 2017 Results - Earnings Call Transcript

2017-11-04 seekingalpha
Good afternoon and welcome to AtriCure's Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session at the end of today’s call. As a reminder, this call is being recorded for replay purposes. (3-1)

AtriCure, Inc. (ATRC) Presents at Morgan Stanley 2017 Global Healthcare Conference (Transcript)

2017-09-13 seekingalpha
Thank you all for joining us on Day 2 of the conference in the evening. Appreciate you being here late in the evening. My name is Jay Chad I'm part of the U.S. Medical Device team here at Morgan Stanley. Two active members of management for AtriCure Mike Carrel and Andy Wade, CEO and CFO, respectively.